CD4
T-cell surface glycoprotein CD4
As of the edition of 20 October 2026, CD4 (T-cell surface glycoprotein CD4, UniProt P01730) has 6 drugs tested at it and 12 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01730
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 85
- Disease areas
- Immune system; Urinary and reproductive; Infections; Skin and connective tissue; Cancer; Blood and lymph; Bones, joints and muscles; Ear, nose and throat
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Semzuvolimab | Stopped | Phase 3 | none listed |
| Ibalizumab | Marketed | Phase 3 | Ends 2030 |
| Zanolimumab | Stopped | Phase 3 | none listed |
| VRC-01LS | Status not established | Phase 2 | none listed |
| Tregalizumab | Stopped | Phase 2 | none listed |
| MTRX1011A | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 1 |
| Undetermined | 6 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Roche | Route A |
| Merus | Route A |
| Emergent Product Development Seattle | Route A |
The other 9 companies at CD4
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at CD4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.